Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UBIFLU

Financiado

Cerrado

Ubiquitin Signalling Pathways Required for Influenza Virus Replication Biologic...

Ubiquitin Signalling Pathways Required for Influenza Virus Replication Biological Characterisation and Identification of Novel Drug Targets Influenza viruses are a significant seasonal disease burden, and provide an ever-present threat of causing severe pandemics with potentially devastating clinical, social, and economic consequences. Vaccines and antivirals are avai... ver más

31/07/2016

UZH

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UZH

39.58K€ | Lider

UNIVERSITY OF GLASGOW

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Inhibicov Hit-to-Lead Development of potent broad-spectrum coronavirus... 150K€ Cerrado

CHUbVi Ubiquitin Chains in Viral Infections 8M€ Cerrado

HIVINNOV Generation of a new class of antiretrovirals targeting HIV... 11M€ Cerrado

FLU-POLII Association between influenza virus RNA polymerase and the t... 222K€ Cerrado

VISION Virus Inhibition by siRNA Optimized by NMR 150K€ Cerrado

ER and Infection ER Function In Virus Infection 183K€ Cerrado

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Influenza viruses are a significant seasonal disease burden, and provide an ever-present threat of causing severe pandemics with potentially devastating clinical, social, and economic consequences. Vaccines and antivirals are available for the prevention and treatment of influenza. However, it often takes too long to manufacture, distribute, and administer an effective strain-matched vaccine under pandemic circumstances, while drug-resistant viruses often emerge against the approved antivirals. Thus, there is urgent need to develop new antivirals with lower chances of selecting drug-resistant strains. Influenza viruses rely extensively on host cell functions, therefore one way to minimise resistance is to target antivirals against host proteins required for virus replication. Here, I will investigate 10 cellular E3 ubiquitin and ubiquitin-like ligases with ‘druggable’ qualities that have been identified in genome-wide siRNA screens as potential host factors required for influenza virus replication. I will confirm their involvement in supporting replication of a broad range of influenza virus strains (including seasonal and pandemic viruses), and attempt to delineate their mechanism of action. By depleting cells of each E3 ligase, and using novel large-scale SILAC- and affinity- based quantitative proteomic techniques, I seek to identify global changes to the cellular ‘ubiquitin-ome’ during virus infection, and correlate these changes with specific host E3 ligases. My work should establish functional and mechanistic links between E3 ligases required for virus replication and the ubiquitin or ubiquitin-like modifications they cause. I hypothesise that there are specific modifications on cellular or viral proteins that are essential for virus replication. Understanding the mechanisms underlying these modifications will provide insights into the interplay between influenza viruses and their hosts, and could represent potential new therapeutic targets.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores